APTAMER GROUP PLC Logo

APTAMER GROUP PLC

Develops custom aptamer-based binders as antibody alternatives for life science applications.

APTA | IL

Overview

Corporate Details

ISIN(s):
GB00BNRRP542
LEI:
213800Y4XGH3WJNBE686
Country:
United Kingdom
Address:
WINDMILL HOUSE, YO10 5BR YORK
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Aptamer Group PLC is a leading developer of custom affinity binders for the life sciences industry through its proprietary Optimer® platform. Optimer binders are next-generation, aptamer-based synthetic ligands engineered to provide high affinity, specificity, and stability. The company offers custom discovery and development services, delivering innovative solutions that serve as alternatives to traditional binders like antibodies. These solutions are utilized across a wide range of applications, including therapeutics, diagnostics, research, and bioprocessing, supporting a global client base of biotechnology and pharmaceutical companies.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for APTAMER GROUP PLC and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-11 08:00
Regulatory News Service
New contract with Metir plc
English 17.0 KB
2025-09-09 08:00
Director's Dealing
Notification of dealings by a director/PDMR
English 23.8 KB
2025-09-02 08:00
Regulatory News Service
Therapeutic development agreement with Invizius
English 18.4 KB
2025-08-28 08:00
Share Issue/Capital Change
Block Listing Interim Review
English 14.9 KB
2025-08-22 08:00
Regulatory News Service
Update on licensing and development progress
English 19.5 KB
2025-08-19 08:00
Share Issue/Capital Change
Exercise of warrants
English 13.5 KB
2025-08-18 08:00
Regulatory News Service
Contract extension with global pharma partner
English 14.7 KB
2025-08-08 08:00
Report Publication Announcement
Investor Technical Webinar
English 13.0 KB
2025-08-07 18:24
Declaration of Voting Results & Voting Rights Announcements
Holding(s) in Company
English 52.2 KB
2025-08-05 09:05
Major Shareholding Notification
Holding(s) in Company
English 22.0 KB
2025-07-31 14:29
Regulatory News Service
Investor Webinar
English 13.7 KB
2025-07-31 08:00
Earnings Release
Trading Update
English 21.0 KB
2025-07-28 13:25
Major Shareholding Notification
Holding(s) in Company
English 52.1 KB
2025-07-24 12:48
Post-Annual General Meeting Information
Result of General Meeting
English 12.4 KB
2025-07-21 08:00
Regulatory News Service
Additional work commissioned by Unilever
English 14.6 KB

Automate Your Workflow. Get a real-time feed of all APTAMER GROUP PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for APTAMER GROUP PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Purple Biotech Ltd. Logo
Develops first-in-class cancer therapies targeting tumor immune evasion and drug resistance.
Israel PPBT
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom N/A
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC Logo
R&D firm using AI and quantum computing to create efficient technologies for Bitcoin mining.
United Kingdom QBT
Quantum Genomics Logo
Develops digital twin solutions to simulate drug effects and personalize treatments.
France ALQGC
QUIA PHARMA AB Logo
Develops enhanced drugs using a patented, releasable pegylation drug delivery platform.
Sweden QUIA
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
Respiratorius AB Logo
Developing innovative drug candidates to enhance standard therapies for aggressive cancers.
Sweden RESP
ROQUEFORT THERAPEUTICS PLC Logo
Developing novel immuno-oncology medicines for hard-to-treat, resistant cancers.
United Kingdom ROQ
United States of America N/A

Talk to a Data Expert

Have a question? We'll get back to you promptly.